Article information
Full text is only aviable in PDF
References
[1]
M.R. Patel, E.D. Peterson, D. Dai, et al.
Low diagnostic yield of elective coronary angiography.
N Engl J Med, 362 (2010), pp. 886-895
[2]
G.A. Diamond, S. Kaul.
Low diagnostic yield of elective coronary angiography.
N Engl J Med, 363 (2010), pp. 93
[3]
J.S. Skinner, L. Smeeth, J.M. Kendall, Chest Pain Guideline Development Group, et al.
NICE guidance. Chest pain of recent onset: assessment and diagnosis of recent onset chest pain or discomfort of suspected cardiac origin.
Heart, 96 (2010), pp. 974-978
[4]
I. Gottlieb, J.M. Miller, A. Arbab-Zadeh, et al.
The absence of coronary calcification does not exclude obstructive coronary artery disease or the need for revascularization in patients referred for conventional coronary angiography.
J Am Coll Cardiol, 55 (2010), pp. 627-634
[5]
K. Nieman, T. Galema, A. Weustink, et al.
Computed tomography versus exercise electrocardiography in patients with stable chest complaints: real-world experiences from a fast-track chest pain clinic.
Heart, 95 (2009), pp. 1669-1675
[6]
C.N. Rathcke, E. Kjoller, N. Fogh-Andersen, et al.
NT-proBNP and circulating inflammation markers in prediction of a normal myocardial scintigraphy in patients with symptoms of coronary artery disease.
PLoS One, 5 (2010), pp. e14196
[7]
A. Peer, G. Falkensammer, H. Alber, et al.
Limited utilities of N-terminal pro B-type natriuretic peptide and other newer risk markers compared with traditional risk factors for prediction of significant angiographic lesions in stable coronary artery disease.
Heart, 95 (2009), pp. 297-303
[8]
H. Hemingway, P. Philipson, R. Chen, et al.
Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease.
PLoS Med, 7 (2010), pp. e1000286
[9]
H. Hemingway, M. Henriksson, R. Chen, et al.
The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model.
Health Technol Assess, 14 (2010), pp. 1-151
[10]
W.E. Boden, R.A. O’Rourke, K.K. Teo, et al.
Optimal medical therapy with or without PCI for stable coronary disease.
N Engl J Med, 356 (2007), pp. 1503-1516
[11]
W.S. Weintraub, J.A. Spertus, P. Kolm, COURAGE Trial Research Group, et al.
Effect of PCI on quality of life in patients with stable coronary disease.
N Engl J Med, 359 (2008), pp. 677-687
[12]
S. Thomas, R. Gokhale, P.J. Devereaux, et al.
Meta-analysis of randomized controlled trialscomparing percutaneous coronary intervention with medical therapy in patients with stable angina.
J Am Coll Cardiol, 57 (2011), pp. E961
[13]
H.C. Wijeysundera, B.K. Nallamothu, H.M. Krumholz, et al.
Meta-analysis: effects of percutaneous coronary intervention versus medical therapy on angina relief.
Ann Intern Med, 152 (2010), pp. 370-379
[14]
National Clinical Guideline Centre: Stable Angina. http://www.nice.org.uk (in production).
[15]
W.B. Kannel, M. Feinleib.
Natural history of angina pectoris in the Framingham study. Prognosis and survival.
Am J Cardiol, 29 (1972), pp. 154-163
[16]
B. Pitt.
ACE inhibitors for patients with vascular disease without left ventricular dysfunction–may they rest in PEACE?.
N Engl J Med, 351 (2004), pp. 2115-2117
[17]
B. Buckley, A.W. Murphy.
Do patients with angina alone have a more benign prognosis than patients with a history of acute myocardial infarction, revascularisation or both?. Findings from a community cohort study.
Heart, 95 (2009), pp. 461-467
[18]
B.S. Buckley, C.R. Simpson, D.J. McLernon, et al.
Five year prognosis in patients with angina identified in primary care: incident cohort study.
BMJ, 339 (2009), pp. b3058
[19]
K.A. Fox.
COURAGE to change practice?. Revascularisation in patients with stable coronary artery disease.
Heart, 95 (2009), pp. 689-692
[20]
M.B. Rothberg, S.K. Sivalingam, J. Ashraf, et al.
Patients’ and cardiologists’ perceptions of the benefits of percutaneous coronary intervention for stable coronary disease.
Ann Intern Med, 153 (2010), pp. 307-313
[21]
E.L. Hannan, M.J. Racz, J. Gold, American College of Cardiology; American Heart Association, et al.
Adherence of catheterization laboratory cardiologists to American College of Cardiology/American Heart Association guidelines for percutaneous coronary interventions and coronary artery bypass graft surgery: What happens in actual practice?.
Circulation, 121 (2010), pp. 267-275
[22]
P.S. Chan, M.R. Patel, L.W. Klein, et al.
Appropriateness of percutaneous coronary intervention.
JAMA, 306 (2011), pp. 53-61
[23]
A.J. Epstein, D. Polsky, F. Yang, et al.
Coronary revascularization trends in the United States, 2001-2008.
JAMA, 305 (2011), pp. 1769-1776
[24]
W.B. Borden, R.F. Redberg, A.I. Mushlin, et al.
Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention.
JAMA, 305 (2011), pp. 1882-1889
[25]
W. Hueb, N. Lopes, B.J. Gersh, et al.
Ten-year follow-up survival of the Medicine. Angioplasty, or Surgery Study (MASS II). A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease.
Circulation, 122 (2010), pp. 943-945
[26]
S. Yusuf, D. Zucker, P. Peduzzi, et al.
Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collab**oration.
Lancet, 344 (1994), pp. 563-570
[27]
E.J. Velazquez, K.L. Lee, M.A. Deja, STICH Investigators, et al.
Coronary-artery bypass surgery in patients with left ventricular dysfunction.
N Engl J Med, 364 (2011), pp. 1607-1616
[28]
R.O. Bonow, G. Maurer, K.L. Lee, STICH Trial Investigators, et al.
Myocardial viability and survival in ischemic left ventricular dysfunction.
N Engl J Med, 364 (2011), pp. 1617-1625
[29]
V. Rizzello, D. Poldermans, E. Biagini, et al.
Prognosis of patients with ischaemic cardiomyopathy after coronary revascularisation: relation to viability and improvement in left ventricular ejection fraction.
Heart, 95 (2009), pp. 1273-1277
[30]
J.C. Fang.
Underestimating medical therapy for coronary disease… again.
N Engl J Med, 364 (2011), pp. 1671-1673
[31]
S.J. Park, Y.H. Kim, D.W. Park, et al.
Randomized trial of stents versus bypass surgery for left main coronary artery disease.
N Engl J Med, 364 (2011), pp. 1718-1727
[32]
M.C. Morice, P.W. Serruys, A.P. Kappetein, et al.
Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel- eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial.
Circulation, 121 (2010), pp. 2645-2653
[33]
E. Boudriot, H. Thiele, T. Walther, et al.
Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis.
J Am Coll Cardiol, 57 (2011), pp. 538-545
[34]
P.W. Serruys, M.C. Morice, A.P. Kappetein, SYNTAX Investigators, et al.
Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.
N Engl J Med, 360 (2009), pp. 961-972
[35]
A.P. Kappetein, T.E. Feldman, M.J. Mack, et al.
Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial.
Eur Heart J, 32 (2011), pp. 2125-2134
[36]
D.J. Cohen, B. Van Hout, P.W. Serruys, for the Synergy between PCI with Taxus and Cardiac Surgery (SYNTAX) Investigators, et al.
Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery.
N Engl J Med, 364 (2011), pp. 1016-1026
[37]
N. Kukreja, P.W. Serruys, B. De Bruyne, ARTS-II Investigators, et al.
Sirolimus-eluting stents, bare metal stents or coronary artery bypass grafting for patients with multivessel disease including involvement of the proximal left anterior descending artery: analysis of the Arterial Revascularization Therapies study part 2 (ARTS-II).
Heart, 95 (2009), pp. 1061-1066
[38]
S.S. Jolly, S. Yusuf, J. Cairns, for the RIVAL Trial Group, et al.
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.
Lancet, 377 (2011), pp. 1409-1420
[39]
C. Pristipino, C. Trani, M.S. Nazzaro, Prospective REgistry of Vascular Access in Interventions in Lazio Region Study Group, et al.
Major improvement of percutaneous cardiovascular procedure outcomes with radial artery catheterisation: results from the PREVAIL study.
Heart, 95 (2009), pp. 476-482
[40]
M. Brueck, D. Bandorski, W. Kramer, et al.
A randomized comparison of transradial versus transfemoral approach for coronary angiography and angioplasty.
JACC Cardiovasc Interv, 2 (2009), pp. 1047-1054
[41]
T.S. Lo, J. Nolan, E. Fountzopoulos, et al.
Radial artery anomaly and its influence on transradial coronary procedural outcome.
Heart, 95 (2009), pp. 410-415
[42]
P.A. Tonino, B. De Bruyne, N.H. Pijls, for the FAME Study Investigators, et al.
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.
N Engl J Med, 360 (2009), pp. 213-224
[43]
N.H. Pijls, W.F. Fearon, P.A. Tonino, FAME Study Investigators, et al.
Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disese: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study.
J Am Coll Cardiol, 56 (2010), pp. 177-184
[44]
W.F. Fearon, B. Bornschein, P.A. Tonino, Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) Study Investigators, et al.
Economic evaluation of fractional flow reserve guided percutaneous coronary intervention in patients with multivessel disease.
Circulation, 122 (2010), pp. 2545-2550
[45]
F. Zhang, L. Dong, J. Ge.
Simple versus complex stenting strategy for coronary artery bifurcation lesions in the drug-eluting stent era: a meta-analysis of randomised trials.
Heart, 95 (2009), pp. 1676-1681
[46]
M. Niemelä, K. Kervinen, A. Erglis, Nordic-Baltic PCI Study Group, et al.
Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: The Nordic-Baltic Bifurcation Study III.
Circulation, 123 (2011), pp. 79-86
[47]
D. Perera, R. Stables, M. Thomas, BCIS-1 Investigators, et al.
Elective intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial.
JAMA, 304 (2010), pp. 867-874
[48]
K.D. Sjauw, T. Konorza, R. Erbel, et al.
Supported high-risk percutaneous coronary intervention with the Impella 2.5 device: The Europella registry.
J Am Coll Cardiol, 54 (2009), pp. 2430-2434
[49]
E.J. Birks.
Left ventricular assist devices.
Heart, 96 (2010), pp. 63-71
[50]
M.T. James, W.A. Ghali, M.L. Knudtson, for the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators, et al.
Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography.
Circulation, 123 (2011), pp. 409-416
[51]
T. Vuurmans, J. Byrne, E.R. Fretz, et al.
Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries).
Heart, 96 (2010), pp. 1538-2154
[52]
M.T. Roe, J.C. Messenger, W.S. Weintraub, et al.
Treatments, trends, and outcomes of acute myocardial infarction and percutaneous coronary intervention.
J Am Coll Cardiol, 56 (2010), pp. 254-263
[53]
S.P. Marso, A.P. Amin, J.A. House, et al.
Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.
JAMA, 303 (2010), pp. 2156-2164
[54]
S.K. Mehta, A.D. Frutkin, J.B. Lindsey, et al.
National Cardiovascular Data Registry. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry.
Circ Cardiovasc Interv, 2 (2009), pp. 222-229
[55]
L. Testa, W.J. Van Gaal, G.G. Biondi Zoccai, et al.
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition.
QJM, 102 (2009), pp. 369-378
[56]
A.S. Hall, J.H. Barth.
Universal definition of myocardial infarction.
Heart, 95 (2009), pp. 247-249
[57]
K. Rahimi, A.P. Banning, A.S. Cheng, et al.
Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study.
Heart, 95 (2009), pp. 1937-1943
[58]
C. Briguori, G. Visconti, A. Focaccio, et al.
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
J Am Coll Cardiol, 54 (2009), pp. 2157-2163
[59]
S.P. Hoole, P.M. Heck, L. Sharples, et al.
Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) study: a prospective, randomized control trial.
Circulation, 119 (2009), pp. 820-827
[60]
K. Bouillon, N. Haddy, S. Delaloge, et al.
Long-term cardiovascular mortality after radiotherapy for breast cancer.
J Am Coll Cardiol, 57 (2011), pp. 445-452
[61]
M. Halle, A. Gabrielsen, G. Paulsson-Berne, et al.
Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries.
J Am Coll Cardiol, 55 (2010), pp. 1227-1236
[62]
C.L. Dubois, C. Pappas, A. Belmans, et al.
Clinical outcome of coronary stenting after thoracic radiotherapy: a case-control study.
Heart, 96 (2010), pp. 678-682
[63]
R.L. Frye, P. August, M.M. Brooks, BARI 2D Study Group, et al.
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
N Engl J Med, 360 (2009), pp. 2503-2515
[64]
G.R. Dagenais, J. Lu, D.P. Faxon, Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group, et al.
Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease.
Circulation, 123 (2011), pp. 1492-1500
[65]
A. Kapur, R.J. Hall, I.S. Malik, et al.
Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial.
J Am Coll Cardiol, 55 (2010), pp. 432-440
[66]
H.M. Blackledge, I.B. Squire.
Improving long-term outcomes following coronary artery bypass graft or percutaneous coronary revascularisation: results from a large, population-based cohort with first intervention 1995-2004.
Heart, 95 (2009), pp. 304-311
[67]
E. Romagnoli, F. Burzotta, C. Trani, et al.
EuroSCORE as predictor of in-hospital mortality after percutaneous coronary intervention.
Heart, 95 (2009), pp. 43-48
[68]
P.W. Serruys, Y. Onuma, S. Garg, et al.
Assessment of the SYNTAX score in the Syntax study.
EuroIntervention, 5 (2009), pp. 50-56
[69]
S. Garg, P.W. Serruys.
Drug-eluting stents: a reappraisal.
Heart, 96 (2010), pp. 489-493
[70]
G.W. Stone, A. Rizvi, W. Newman, SPIRIT IV Investigators, et al.
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
N Engl J Med, 362 (2010), pp. 1663-1674
[71]
E. Kedhi, K.S. Joesoef, E. McFadden, et al.
Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.
Lancet, 375 (2010), pp. 201-209
[72]
K. Rasmussen, M. Maeng, A. Kaltoft, for SORT OUT III Study Group, et al.
Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial.
Lancet, 375 (2010), pp. 1090-1099
[73]
P.W. Serruys, S. Silber, S. Garg, et al.
Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
N Engl J Med, 363 (2010), pp. 136-146
[74]
A.K. Jain, C. Lotan, I.T. Meredith, E-Five Registry Investigators, et al.
Twelve-month outcomes in patients with diabetes implanted with a zotarolimus-eluting stent: results from the E-Five Registry.
Heart, 96 (2010), pp. 848-853
[75]
R.A. Byrne, S. Kufner, K. Tiroch, ISAR-TEST-3 Investigators, et al.
Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results.
Heart, 95 (2009), pp. 1489-1494
[76]
P.W. Serruys, J.A. Ormiston, Y. Onuma, et al.
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods.
Lancet, 373 (2009), pp. 897-910
[77]
G.W. Stone, B. Witzenbichler, G. Guagliumi, on behalf of the HORIZONS-AMI Trial Investigators, et al.
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.
Lancet, 377 (2011), pp. 2193-2204
[78]
C. Spaulding, J. Rosencher, O. Varenne.
Use of drug eluting stents in ST segment elevation myocardial infarction.
Heart, 96 (2010), pp. 1073-1077
[79]
C. Kaiser, S. Galatius, P. Erne, for the BASKET-PROVE Study Group, et al.
Drug-eluting versus bare-metal stents in large coronary arteries.
N Engl J Med, 363 (2010), pp. 2310-2319
[80]
M. Pfisterer, H.P. Brunner-La Rocca, P. Rickenbacher, et al.
Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter?. Three-year follow-up of BASKET.
Eur Heart J, 30 (2009), pp. 16-24
[81]
B. Cortese, A. Micheli, A. Picchi, et al.
Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study.
Heart, 96 (2010), pp. 1291-1296
[82]
M. Unverdorben, C. Vallbracht, B. Cremers, et al.
Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis.
Circulation, 119 (2009), pp. 2986-2994
[83]
F. Liistro, M. Fineschi, S. Grotti, et al.
Long-term effectiveness and safety of sirolimus stent implantation for coronary in-stent restenosis: results of the TRUE (Tuscany Registry of sirolimus for unselected in-stent restenosis) registry at 4 years.
J Am Coll Cardiol, 55 (2010), pp. 613-616
[84]
K.J. Harjai, C. Shenoy, P. Orshaw, et al.
Dual antiplatelet therapy for more than 12 months after percutaneous coronary intervention: insights from the Guthrie PCI Registry.
Heart, 95 (2009), pp. 1579-1586
[85]
S.J. Park, D.W. Park, Y.H. Kim, et al.
Duration of dual antiplatelet therapy after implantation of drug-eluting stents.
N Engl J Med, 362 (2010), pp. 1374-1382
[86]
P.M. Ho, T.T. Tsai, T.M. Maddox, et al.
Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care.
Circ Cardiovasc Qual Outcomes, 3 (2010), pp. 261-266
[87]
A. Migliorini, R. Valenti, R. Marcucci, et al.
High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease.
Circulation, 120 (2009), pp. 2214-2221
[88]
M.J. Price, P.B. Berger, P.S. Teirstein, GRAVITAS Investigators, et al.
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
JAMA, 305 (2011), pp. 1097-1105
[89]
L. Bonello, A. De Labriolle, M. Scheinowitz, et al.
Emergence of the concept of platelet reactivity monitoring of response to thienopyridines.
Heart, 95 (2009), pp. 1214-1219
[90]
J.P. Collet, J.S. Hulot, A. Pena, et al.
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.
Lancet, 373 (2009), pp. 309-317
[91]
J.L. Mega, S.L. Close, S.D. Wiviott, et al.
Cytochrome p-450 polymorphisms and response to clopidogrel.
N Engl J Med, 360 (2009), pp. 354-362
[92]
A.R. Shuldiner, J.R. O’Connell, K.P. Bliden, et al.
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
JAMA, 302 (2009), pp. 849-857
[93]
G. Paré, S.R. Mehta, S. Yusuf, et al.
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
N Engl J Med, 363 (2010), pp. 1704-1714
[94]
L. Wallentin, S. James, R.F. Storey, for the PLATO Investigators, et al.
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Lancet, 376 (2010), pp. 1320-1328
[95]
M. Würtz, E.L. Grove, S.D. Kristensen, et al.
The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease.
Heart, 96 (2010), pp. 368-371
[96]
M. Charlot, O. Ahlehoff, M.L. Norgaard, et al.
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
Ann Intern Med, 153 (2010), pp. 378-386
[97]
D.L. Bhatt, B.L. Cryer, C.F. Contant, for the COGENT Investigators, et al.
Clopidogrel with or without omeprazole in coronary artery disease.
N Engl J Med, 363 (2010), pp. 1909-1917
[98]
J.M. Scheiman, P.J. Devereaux, J. Herlitz, et al.
Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON).
Heart, 97 (2011), pp. 797-802
[99]
T. Gremmel, S. Steiner, D. Seidinger, et al.
Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
Heart, 96 (2010), pp. 186-189
[100]
J.M. Siller-Matula, I. Lang, G. Christ, et al.
Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
J Am Coll Cardiol, 52 (2008), pp. 1557-1563
[101]
A.L. Shroyer, F.L. Grover, B. Hattler, Veterans Affairs Randomized On/Off Bypass (ROOBY) Study Group, et al.
On-pump versus off-pump coronary-artery bypass surgery.
N Engl J Med, 361 (2009), pp. 1827-1837
[102]
E. Kozora, S. Kongs, J.F. Collins, et al.
Cognitive outcomes after on- versus off-pump coronary artery bypass surgery.
Ann Thorac Surg, 90 (2010), pp. 1134-1141
[103]
C.H. Møller, M.J. Perko, J.T. Lund, et al.
No major differences in 30-day outcomes in high-risk patients randomized to off-pump versus on-pump coronary bypass surgery: the best bypass surgery trial.
Circulation, 121 (2010), pp. 498-504
[104]
C.H. Møller, M.J. Perko, J.T. Lund, et al.
Three-year follow-up in a subset of high-risk patients randomly assigned to off-pump versus on-pump coronary artery bypass surgery: the Best Bypass Surgery Trial.
Heart, 97 (2011), pp. 907-913
[105]
A. Chukwuemeka.
Think “better bypass” before thinking “off-pump”?.
Heart, 95 (2009), pp. 955-956
[106]
F. Biancari, R. Rimpiläinen.
Meta-analysis of randomised trials comparing the effectiveness of miniaturised versus conventional cardiopulmonary bypass in adult cardiac surgery.
Heart, 95 (2009), pp. 964-969
Copyright © 2011. Sociedade Portuguesa de Cardiologia
